Tiziana Life Sciences Ltd

NasdaqCM:TLSA Stock Report

Market Cap: US$150.0m

Tiziana Life Sciences Past Earnings Performance

Past criteria checks 0/6

Tiziana Life Sciences has been growing earnings at an average annual rate of 17.1%, while the Biotechs industry saw earnings growing at 36.2% annually.

Key information

17.14%

Earnings growth rate

25.78%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equity-35,444.23%
Net Marginn/a
Last Earnings Update31 Dec 2025

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Jun 14

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

Summary Tiziana is developing foralumab, a fully human anti-CD3 monoclonal antibody, for non-active secondary progressive multiple sclerosis patients, with key data expected in 2026. A phase 2 trial of foralumab in early-stage Alzheimer's Disease is set to begin in 2025, targeting microglial activation and neuroinflammation. The global Alzheimer's Disease market is expected to reach $23.8 billion by 2031. Upcoming catalysts include the Alzheimer's phase 2 trial initiation and a CEO presentation of MS program data at Bio International Convention in June 2025. Read the full article on Seeking Alpha
Seeking Alpha • Dec 24

Tiziana Life Sciences: Awaiting Data Of Foralumab For Secondary Progressive Multiple Sclerosis

Summary Tiziana Life Sciences is developing foralumab, an anti-CD3 monoclonal antibody, for treating neurodegenerative diseases like SPMS and Alzheimer's, with promising early results. Positive Phase 2 trial results in SPMS could attract investor interest due to the large market and lack of approved drugs for non-active SPMS. The company faces financial challenges with high cash burn and potential shareholder dilution despite recent funding efforts and an at-the-market sales agreement. Given the financial risks and pending trial results, I currently rate Tiziana a Hold, awaiting more data from the Phase 2 SPMS trial. Read the full article on Seeking Alpha
Analysis Article • Sep 19

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jun 03

We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jan 16

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Oct 12

Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy

Tiziana Life Sciences (NASDAQ:TLSA) is trading 11.2% higher premarket after it plans to submit an application to begin Phase 1 trial of intranasal foralumab in Alzheimer's disease. Tiziana plans on filing the Investigational New Drug Application for Alzheimer’s disease by Q3 2023 upon the completion of requested toxicology studies, and will start Phase 1 program by the end of 2023.
Seeking Alpha • Sep 23

Tiziana chief medical officer further increases holdings in company

Matthew Davis, chief medical officer of biotechnology company Tiziana Life Sciences (NASDAQ:TLSA), has purchased 75,000 shares of the company's common stock at $0.83 per share. The transaction increases Davis' total holding in the firm to 175,000 common shares. Earlier this month, Davis bought 100K TLSA shares at $0.76 per share.
Seeking Alpha • Sep 16

Tiziana Life Sciences executive chairman further raises stake in company

Tiziana Life Sciences (NASDAQ:TLSA) has announced a share purchase by its executive chairman, Gabriele Cerrone. Panetta Partners, an entity in which Cerrone has a beneficial interest, purchased 29,318 common shares priced between $0.78 and $0.81 per share. The acquisition raises Cerrone's interests in the firm from 37.70% to 37.72%.
Seeking Alpha • Aug 25

Tiziana executive chairman raises stake in company again, buys more shares

Tiziana Life Sciences (NASDAQ:TLSA) said that its Executive Chairman Gabriele Cerrone bought additional common shares, raising stake in the company to 37.70% from 37.61%. The company added that Panetta Partners, an entity in which Cerrone has a beneficial interest, bought 80K shares at $0.75 apiece. Earlier in August, Tiziana noted that Panetta had bought 20K shares which had raised Cerrone's interest to 37.61%.
Seeking Alpha • Aug 17

Tiziana Life Sciences discloses share purchase by executive chairman

Tiziana Life Sciences (NASDAQ:TLSA) has announced a purchase of 20K common shares by Panetta Partners, an entity in which executive chairman Gabriele Cerrone holds a beneficial interest. The shares were acquired at $0.75 each. The transaction brings Mr Cerrone's interests in the firm from 37.60% to 37.61%.
Analysis Article • Aug 15

Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jul 15

Tiziana Life Sciences CEO Kunwar Shailubhai resigns

Tiziana Life Sciences (NASDAQ:TLSA) said on Friday that Kunwar Shailubhai as Chief Executive Officer, Chief Scientific Officer and Board director had resigned, effective as of August 1. The company said Shailubhai resigned due to personal reasons. The company's board has appointed Gabriele Cerrone as interim Chief Executive Officer to lead the Company through the period of transition.

Revenue & Expenses Breakdown

How Tiziana Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:TLSA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 250-181110
30 Sep 250-16128
30 Jun 250-13136
31 Mar 250-12126
31 Dec 240-12115
30 Sep 240-1396
30 Jun 240-1487
31 Mar 240-1698
31 Dec 230-18108
30 Sep 230-19108
30 Jun 230-20109
31 Mar 230-17611
31 Dec 220-15213
30 Sep 220-13114
30 Jun 220-11015
31 Mar 220-17714
31 Dec 210-231413
30 Sep 210-312312
30 Jun 210-383111
31 Mar 210-32288
31 Dec 200-26246
30 Sep 200-18164
30 Jun 200-1073
31 Mar 200-1073
31 Dec 190-964
30 Sep 190-864
30 Jun 190-855
31 Mar 190-855
31 Dec 180-846
30 Sep 180-846
30 Jun 180-956
31 Mar 180-956
31 Dec 170-946
30 Sep 170-1156
30 Jun 170-1266
31 Mar 170-1055
31 Dec 160-954
30 Sep 160-945
30 Jun 160-936
31 Mar 160-1148
31 Dec 150-1339
30 Sep 150-1147

Quality Earnings: TLSA is currently unprofitable.

Growing Profit Margin: TLSA is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: TLSA is unprofitable, but has reduced losses over the past 5 years at a rate of 17.1% per year.

Accelerating Growth: Unable to compare TLSA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TLSA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).

Return on Equity

High ROE: TLSA has a negative Return on Equity (-35444.23%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/22 11:45
End of Day Share Price 2026/06/22 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tiziana Life Sciences Ltd is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Elemer PirosLucid Capital Markets